Jan Skvarka - May 11, 2021 Form 4 Insider Report for Trillium Therapeutics Inc. (TRIL)

Role
President and CEO, Director
Signature
/s/ James Parsons, Attorney-in-Fact
Stock symbol
TRIL
Transactions as of
May 11, 2021
Transactions value $
-$1,149,139
Form type
4
Date filed
5/13/2021, 04:12 PM
Next filing
Nov 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRIL Common Shares Options Exercise $39K +87.5K $0.45* 87.5K May 11, 2021 Direct F1
transaction TRIL Common Shares Options Exercise $6.03K +19.2K +21.94% $0.31* 107K May 11, 2021 Direct F2
transaction TRIL Common Shares Sale -$982K -107K -100% $9.20* 0 May 11, 2021 Direct F3
transaction TRIL Common Shares Options Exercise $7.47K +23.8K $0.31* 23.8K May 12, 2021 Direct F2
transaction TRIL Common Shares Sale -$220K -23.8K -100% $9.24* 0 May 12, 2021 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRIL Stock Option (Right to Buy) Options Exercise $0 -87.5K -7% $0.00 1.16M May 11, 2021 Common Shares 87.5K $0.45 Direct F1, F5
transaction TRIL Stock Option (Right to Buy) Options Exercise $0 -19.2K -8% $0.00 221K May 11, 2021 Common Shares 19.2K $0.31 Direct F2, F5
transaction TRIL Stock Option (Right to Buy) Options Exercise $0 -23.8K -10.78% $0.00 197K May 12, 2021 Common Shares 23.8K $0.31 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD.
F2 The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.36 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.